首页> 中文期刊> 《中国医学创新》 >阿立哌唑合并康复训练改善精神分裂症患者生活质量的临床研究

阿立哌唑合并康复训练改善精神分裂症患者生活质量的临床研究

         

摘要

Objective:To explore the effect of aripiprazole combined with rehabilitation training in patients with schizophrenia quality of life of the spirit.Method:Met the Chinese classification and diagnostic criteria of mental disorders Third Edition(CCMD-3)criteria for the diagnosis of 90 patients with schizophrenia were randomly divided into two groups,aripiprazole and clozapine in the treatment of,a total of 8 weeks,two groups were psychiatric rehabilitation training. The positive and negative symptoms scale before and after treatment(PANSS)was introduced in June to assess the efficacy,the side effects scale(TESS)assessment of adverse reactions,the WHO quality of life scale(WHOQOL-100)assessment of quality of life.Result:Aripiprazole group and clozapine group markedly effective rate were 73.3%and 75.6%,with no significant difference between two groups(P>0.05);4,8 weeks after treatment,two groups of PANSS scale scores were decreased than that before treatment(P<0.05),but after 8 weeks of treatment with aripiprazole group negative symptoms and general spirit pathology is clozapine group had significant difference(P<0.05);the incidence rate of adverse reaction of aripiprazole group was significantly lower than that in clozapine group(P<0.05);after 6 months of treatment in the two groups(WHOQOL-100)scale in all areas than before treatment was statistically significant(P<0.05),but aripiprazole group in physiological field,psychological field,the field, social relations the spiritual pillar,a lower quality of life than the clozapine group had significant difference(P<0.05).Conclusion:Aripiprazole in the treatment of schizophrenia with clozapine is similar,less adverse reaction,combined with rehabilitation therapy can significantly improve the life quality of schizophrenia patients.%  目的:探讨阿立哌唑合并康复训练对精神分裂症患者生活质量的影响。方法:将符合中国精神障碍分类与诊断标准第3版(CCMD-3)诊断标准的精神分裂症患者90例随机分为两组,分别给予阿立哌唑与氯氮平治疗,共观察8周,两组患者均予以精神康复训练。于治疗前及治疗后6个月采用阳性与阴性症状量表(PANSS)评定疗效,采用副反应量表(TESS)评定不良反应,采用世界卫生组织编制的生活质量量表(WHOQOL-100)评定生活质量。结果:阿立哌唑组及氯氮平组的显效率分别为73.3%和75.6%,两组差异无统计学意义(P>0.05);治疗后4、8周,两组PANSS量表各项因子分均较治疗前下降(P<0.05),但治疗后8周阿立哌唑组阴性症状及一般精神病理分较氯氮平组差异有统计学意义(P<0.05);阿立哌唑组不良反应发生率显著低于氯氮平组(P<0.05);治疗6个月后两组在(WHOQOL-100)量表各领域均较治疗前有统计学意义(P<0.05),但阿立哌唑组在生理领域、心理领域、社会关系领域、精神支柱、生活质量方面较氯氮平组差异有统计学意义(P<0.05)。结论:阿立哌唑治疗精神分裂症疗效与氯氮平相仿,不良反应少,合并精神康复治疗可显著改善精神分裂症患者的生活质量。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号